Differences in central actions of arachidonic acid and prostaglandin F\(_{2\alpha}\) between spontaneously hypertensive and normotensive rats by Sirén, Anna-Leena
Life Sciences, Vo1. 30, pp. 503-513 
Printed in the U.S.A. 
Pergamon Press 
DIFFERENCES IN THE CENTRAL ACTIONS OF ARACHIDONIC ACID AND 
PROSTAGLANDIN F2a BETWEEN SPONTANEOUSLY HYPERTENSIVE 
AND NORMOTENSIVE RATS 
Anna-Leena Siren 
Departm:mt of Phannaco1ogy, University of Oulu, 
Kajaanintie 52 D, SF-90220 Ou1u 22, Finland 
(Received in final form December 15, 1981) 
SUMMARY 
Prostag1andin F2a (PGFZJ) is one of the most common metabo1ites 
of arachidonic acid (M) in rat brain. When administered intracere-
broventricularly (i.c.v.) to rats, both AA and PGFal exert dose-re-
1ated hypertensive, tachycardic and hyperthermic effects. Metabolie 
alterations in the endogenaus formation of some prostaglandins in 
the brain-stem of spontaneously hypertensive rats (SHR) have been 
reported. Therefore the central effects of AA and PGF 2a. on blood 
pressure, heart rate and body temperature were studied both in SHR 
and nonootensive Wistar rats (NR) tmder urethane-anaesthesia. The 
hypertensive effect of AA i.c.v. (0.01-100 ~/rat) was larger in mag-
ni tude in SHR than in NR, but there was no significant difference 
in the M-induced changes of heart rate and body temperature between 
the groups. Pretreatment of NR wi th soditm1 :meclofenamate (1 mg/rat 
i.c.v.) antagonised the central effects of M indicating that these 
effects are not due to M itself but to its conversion to prosta-
glandins. Unlike the effects of AA, the central hypertensive, 
tachycardic and hyperthennic responses to PGF2a (0.5-50 l-lg/rat i.c.v .) 
were significantly attenuated in SHR. The present results obtained 
with M are conpatible with the previous assumption that the synthe-
sis of prostaglandins in the brain of SHR might differ from that in 
NR. The results also demonstrate that the central effects of PGFza 
are reduced in SHR. 
Prostaglandin F2a (PGF 2a), PGD2 and thronboxane A2 (TxA2 ) are the most com-
mon metaboli tes of arachidon1c acid (M) in rat brain (1, 2) , but PGE 2 and PGI 2 
arealso formed (2,3). When administered into the lateral cerebral ventricle 
(i.c.v.) of urethane-anaesthetised nol11Dtensive Wistar rats (NR), M, PGF 2a and 
PGE 2 induce dose-re1ated increases in blood pressure, heart rate and body tem-
perature (4,5,6), whereas PGI2 lowers the blood pressurealso upon central ad-
ministration (7, 8). Though PGD2 is the rost cormoon prostaglandin type of the 
rat brain (1,3), it has only slight or no central effect on the cardiovascular 
system of the rat (6,9). Recent sturlies have shown that the endogenaus form-
ation of PGE 2 and TxB 2 is increased and the PGI 2/PGE2 ratio is decreased in the 
brain-stem of stroke-resistant spontaneously hypertensive rats (SHR) (10). The 
synthesis of PGE2 and PGF~ is altered also in the brain, aorta and kidney ho-
mogenates of SHR (11). Furthermore, the hypotensive effect of intra-arterially 
injected AA is attenuated in SHR (12). Recently it has been also reported that 
the central presser response to PGE 2 is !arger in ma.gni tude in SHR than in NR (13), but the central effects of M or i ts other retaboli tes than PGE2 in SHR 
have not been reported. 
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In the present study increasing doses of M or PGF2l were adrninistered 
i.c.v. to both SHR and NR under urethane anaesthesia in order to obtain com-
plete simultaneaus dose-response curves for blood pressure, heart rate and body 
tempera ture. 
MATERIALS AND METHODS 
Male spontaneously hypertensive rats of Okamoto-Aoki strain, 250-330 g,lZ-
15 weeks of age, were purchased fromM~llegaards Avlslaboratorier, DK-4623, Ll. 
Skensved, Denrnark. Age-matched male nonnotensive Wistar rats, 290-350 g, were 
used as their controls. SHR had an average systolic blood pressure of 176 ± 3 
rnm Hg(! s.e.m.)(n=l2) which was significantly greater (p<O.OOl) than the cor-
responding level of 140 ± 5 rnm Hg in NR (n=9). Heart rate in SHR (390 ± 8 
beats/min) was also significantly greater (p<O.OS) than the corresponding level 
of 360 ! 10 beats/min in NR. The rats were accomm::>dated to standard a.nDient 
conditions for at least one week before the experiJrents. The 1ights were on 
from 6 a.m. to 6 p.m. and the room was completely dark during the remaining 12 
hours. The tempera ture was kept a t 2 2 °C and the relative humidi ty a t 40% • The 
rats received standard rat pellets (Hankkija Oy, Helsinki) and tap water ad li-
bitl.Dn. The rats were anaesthetised with urethane (1.5 g/kg intraperitoneally). 
~rachea was cannulated with a polyethylene tube and the rats were allowed 
to breathe spontaneously. The rean arterial blood pressure was rneasured from 
the left femoral artery by means of a pressure transducer (Hewlett Packard 1280) 
and the heart rate was calculated from the pulse waves by means of a rate com-
puter (Hewlett Packard 8812 A). The femoral vein was cannulated for intrave-
nous injections. The rats were IIPunted in a Stereotaxie instnnnent and til ted 
caudally so that the body forred an angle of 10 degrees with the horizontal 
plane. Intracerebroventricular injections were performed as described by Paak-
kari (14). Briefly, an injection needle was introduced into the right lateral 
ventricle of the brain. A polyethylene catheter, filled with the drug or con-
trol solution to be infused, was attached to the needle and the desired amount 
of the solution was allowed to flow slowly by virtue of the hydrostatic pres-
sure. The infusion was s topped by closing the upper end of the ca theter. The 
proper position of the needle tip was ascertained at the end of each experiment 
by an injection of dye (Giemsa Solution, Merck) into the cerebral ventricle. 
The body temperature was rneasured rectally with a temperature recorder (ELLAB 
instrt.uOOnts, type TE 3, Copenhagen), a probe being introduced Sem into the rec-
ttnn. A 60 W heating laJil> was placed 20 cm above the rat. Experiments on con-
trol rats showed that this distance of the heating lamp was adequate to keep 
the body temperature at 36.1 ± 0.3°C (mean ± s.e.m.) in an ambient temperature 
of 22°C. 
Administration of drugs 
The stock solution of M, grade 1, 99% (Sigma Chemical Co.) , 100 mg/ml ,was 
made in absolute ethanol and kept at-20°C. The dilutions were made fresh1y each 
day in 0. 9% (w/v) NaCl (saline) or in a :roodified Krebs-Ringer bicarbonate buffer 
(NaCl 117.0 mM, KCl 2.95 rnM, CaCl2 1.44 mM, KH2P04 0.01 rnM, MgS04x1H20 1.12 mM, 
and NaH003 23.6 mM, pH 7.32)to simulate the concentrations found in the cerebra-
spinal fluid (15). Increasing doses of AA were injected i.c.v. in a volume of 
10 lJl or intravenously (i.v.) in a voll..D11e of 0.15 ml at 20-30 min intervals. 
The control animals received the sruoo vo1l..D"OOs of the corresponding buffer solu-
tion i.c.v. and saline solution i.v. in each case. 
PGF2a, 5 mg/~ (Astra), was diluted with the modified Krebs-Ringer bicar-
bonate bufferandwas injected i.c.v. at 30 min intervals. 
Sodium rneclofenamate monohydrate (Parke, Davis & Co.) was dissolved in sa-
line rotd was adminis terered i . c. v. 20 min before the adminis tra tion of M i . c. v. 
Vol. 30, No. 6, 1982 Central Prostaglandins and Hypertension 505 
in order to study the influence of this agent on the central effects of M. 
The Student' s t-test was used to calculate the statistical significance of 
the differences between the control and experirenta1 groups. 
RESULTS 
Effects of arachidonic acid 
Effects of arachidonic acid in normotensive rats 
Intracerebroventricularly, AA at the doses of 0.1-100 ~g/rat raised the 
blood pressure and heart rate, and at the doses of 1-100 ~g also the bo~/ tem-
perature of urethane-anaesthetised NR. The maximum increase in blood pressure 
and heart rate was achieved in 15 min. Upon intravenous administrations the 
same doses of AA had negligible hypotensive and bradycardic effects. Intrave-
nously administered AA had no significant effect on body temperature either. 
(FIG 1) 
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FIG 1 
Inf1uence of AA on b1ood pressure 
(B.P.), heart rate (H.R.) and body tem-
pera ture (B. T.) in urethane-anaes theti-
sed NR. Increasing doses of AA were ad-
ministered i.c.v. C•-•) or i.v. (ä-A) 
a t 20 min in tervals . The control group 
(o-o) received vehicles i.c.v. and i.v. 
The changes 15 min after each injection 
are shown. The initia1 1eve1s for B.P., 
H.R. and B.T. (rneans ± s.e.m.) were 104 
= 4 nnn Hg, 440 ± 10 beats/min and 35.6 
± 0.2 oe in the contro1 group, 105 ± 7 mm 
Hg, 440 :!10 beats/min and 35.7 ± 0. 2 oe 
in the M i.c.v. group and 103 :t 5 nnn Hg, 
440 ± 5 beats/rnin and 35.7 ± 0.2°C in 
the AA i .c. v. group. The significance 
of the AA-induced changes is shown by 
asterisks; • p<0.05, •• p<0.005 and 
•••p<O.OOl vs. contro1 group. The 
differences in the cardiovascular chan-
ges be tween AA i . c. v. and i • v. groups 
are significant at the p<0.05-0.001 lev-
e1. Vertical bars indicate s.e.m. The 
AA groups comprised 6-7 rats, control 
group 11 rats, except for the last dose 
(4 rats). 
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Sodium meclofenamate (1 mg/rat i.c.v.) reversed the hypertensive and 
tachycardic effects of i.c.v. administered AA and almost wholly antagonised 
central effect of AA on body temperature (FIG 2). 
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FIG 2 
Influence of AA i.c.v. on blood 
pressure (B.P.), heart rate (H.R.) and 
body temperature (B.T.) in sodium meclo-
fenamate pretreated rats and their con-
trols. Sodium meclofenamate, 1 mg/rat 
(•-• or saline (o-o) was injected 
i.c.v. 20 min before AA administrations. 
Increasing doses of M were administered 
i.c.v. at 20 nän intervals. The changes 
15 min after each injection are shown. 
The initial levels for ß.P., H.R. and B. 
T. (means ± s .e .m.) were lOS ± 7 nun Hg, 
440 ± 10 beats/mdn and 35.7 ± 0.2°C in 
the control group and 104 ± 6 nun Hg, 450 
± 10 beats/min and 35.9 ± 0.2°C in the 
sodium meclofenamate pretreated group • 
The significance of the differences be-
tween the groups is shown by asterisks; 
* p <0 • 0 5 , • • p < 0 . 00 5 and • •• 
p<O.OOl. Verticals bars indicate s.e.m. 
Each group comprised 6 rats. 
Effects of arachidonic acid in spontaneously hypertensive rats 
Effect of AA on blood pressure (FIG 3) 
The i.c.v. administration of AA at the doses of 0.01-100 ~g/rat increased 
the blood pressure of both SHR and NR in a dose-related manner. The maximum 
effect was reached 10-15 min after each injection. The AA-induced rises of 
blood pressure were significantly greater in magnitude in SHR than in NR. 
Effect of AA on heart rate (FIG 4) 
AA at the i.c.v. doses of 0.01-100 vg/rat dose-dependent1y increased the 
heart rate of NR. In SHR the AA-induced rises of heart rate were not clearly 
dose-related. 
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FIG 3 
Effect of AA i.c.v. on 
blood pressure in urethane-an-
aesthetised SHR and NR. In-
creasing doses of M were ad-
ministered i.c. v. to SHR(•-•) 
or NR (o-o) a.t 30 min inter-
vals . The control NR ( o-o) 
recei ved the sa:rm voltDOO of ve-
hicle i.c.v. in each case. The 
maxintum changes 10-15 min af-
ter each injection are shown. 
The ini tial blood pressure 
level (mean ± s.e.m.) was 100 
± 4 nnn Hg in the control NR, + 
100 ± 4 mm Hg in NR and 109 -
8 liiil Hg in SHR. The hypertens-
ive effect of AA (0.1-100 vg) 
in NR is significant at the p< 
0.05 leve1 as ceropared to the 
control group. Differences in 
1 the M-induced changes between 
SHR and NR are shown by as ter-
100isk; *p<O.OS. Vertica1 bars 
indica te s • e .m. Each group 
comprised 6 rats, except for 
the control group (5 rats). 
FIG 4 
Effect of AA i.c.v. on 
heart rate in urethane-anaes-
thetised SHR and NR. Increas-
ing doses of AA were adminis-
tered i.c.v. to SHR (.---e) or 
I NR (o-o)at 30 min intervals • The control NR (o-o) recei v-ed the same voll..uoo of vehicle 1 i.c.v. in each case. The max-~ imum changes 10-20 mi.n after 
initial heart rate level (mean 
0 ± s .e .m.) was 430 ± 10 beats/ 1 rnin in the control NR, 440 :1:10 
beats/min in NR and 380 ± 10 
0---- beats/min in SHR. The differ-
JL ence in the initial heart rate 
between SHR and NR is signif-
icant at the p<O.OOS 1evel. 
The tachycardic effect of M 
(0.01-100 ~g) in NR is signif-
L_j/ 1 1 icant at the p<O.OS level as 
-::-71""'"_... _____ ......_ _ ____.~,....__~ conq:>ared to the control group. 
0 0.01 0.1 10 100 Vertical bars indicate s .e .m. 
Each group comprised 6 ·rats, 
A A ( J.Jg/rat i.c.v.) Except for the control group (5 rats). 
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Effect of AA on body temperature (FIG 5) 
M induced a slight but statistically significant hyperthennic effect in 
NR. In SHR i.c.v. administered AA had only negligible effect on body tempera-
ture. 
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FIG 5 
Effect of AA i.c.v. on body 
temperature in urethane-anaes-
thetised SHR and NR. Increas-
ing doses of AA were adminis-
tered i.c.v. to SHR C•-•) or 
NR ( o -o) a t 30 min interva1s . 
The control NR (o-o) receiv-
ed the same volume of vehic1e 
in each case. The changes 10-
20 rrdn after each injection 
are shown. The ini tial body 
+ ternperature (mean - s.e.m.)was 
35.4 !0.3°C in the control NR, 
36.2 - 0.2°C in NR and 35.3 : 
0. 3 °C in SHR. The differences 
in the initia1 body temperatu-
res are not statistically sig-
nificant. The hyperthermic 
effect of AA (0.1-100 ~g)in NR 
is significant at the p<O.OS-
LJL 1 1 0.001 1evel as compared to the O~r-O---L.0-1--0....1.-1 --L----10'---1---'00 control group. Differences in . the AA-induced changes between 
SHR and NR are not statistic-
AA (l-Jglrat i.c.v.) 
a1ly significant. Vertical 
bars indicate s.e.m. Each 
group comprised 6 rats, except 
for the control group (5 rats). 
Effects o~ prostaglandin F2ain spontaneously hypertens1ve rats 
Effect of PGF2a on b1ood pressure (FIG 6) 
PGF 2a at the i.c.v. doses of 0.5-50 ~g/rat induced a dose-dependent rise 
of blood pressure in NR. The maximurn effect was reached appro:xirnately 15 min 
after each injection. The administration of PGF 2a at the same i.c.v. doses to 
SHR did not alter the blood pressure. The ini tial blood pressure before the 
administrations of PGF2a was significantly higher in SHR than in NR in spi te of 
the urethane anaesthesia. 
Effect of PGF 2a an heart rate (FIG 7) 
PGFZ) dose-dependently increased the heart rate, when administered i.c.v. 
at the doses of 0.5-50 ~g/rat to NR. In SHR the same i.c.v. doses failed to 
affect the heart rate. 
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FIG 6 
Effect of PGF2a i.c.v. on 
b1ood pressure in urethane-an-
aesthetised SHR and NR. In-
creasing doses of PGF2a were 
administered i.c.v. to SHR 
(e-e) or NR (o-o) at 30min 
interva1s. 1he maximurn changes 
about lSmin after each inject-
ion are shown. The ini tial 
blood p;essure (mean ± s.e.m.) 
was 90 - 5 nun Hg in NR and 115 
! 9 nnn Hg in SHR. The differ-
ence in the ini tial blood 
pressure between the groups is 
significant at the p<O. OS lev-
e1. The differences in the 
PGF2(l-induced changes between 
SHR and NR are shown by aster-
isks; • p<O .OS and •• p<O .005. 
Vertica1 bars indicate s.e.m. 
Each group comprised 6 rats. 
FIG 7 
Effect of PGF 20 i .c. v. on 
T heart rate in urethane-anaes-thetised SHR and NR. Increas-
T _,_-----o ing doses of PGF 2Cl were admin-
Q l istered i.c.v. to SHR (e-e) 
/
.L or NR (o-o) at 30 min inter-
va1s. The maxinn.un changes a-
bout 15 min after each inject-T, ion are shown. The ini tial 
o heart rate (rean ± s.e.m.) was l 430 .! 10 beats/min in NR and 
410 ± 10 beats/min in SI-IR. The 
.-. ;;;:..•--- ••• difference ~n the ini t~al . ~ I~ heart rate 1s not stat1st1c-
~ .... ally significant. The differ-
...L. ences in the PGF2<l-induced 
changes between SHR and NR are 
shown by asterisks; • p<O.OS 
and • • • p<O. 001. Vertica1 
0.5 5 50 bars indicate s.e.m. Each group cornprised 6 rats. 
PG F2cx (t.Jg/ra t i.c v.) 
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Effect of PGF2a on body temperature (FIG 8) 
PGF~, 0.5-50 ~g/rat i.c.v. induced a substantial hypertherrrcic effect in 
NR. In SHR the same doses of PGF2a had no significant effect on body ternpera-
ture 
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FIG 8 
Effect of PGF2a i.c.v. on 
body temperature in urethane-
anaesthetised SHR and NR. In-
creasing doses of PGF2a were 
administered i.c.v.to SHR(• •) 
or NR (0 o) at 30 min inter-
vals. The changes about 15 min 
after each injection are shown. 
The ini. tial body tempera ture 
(mean! s.e.m.) was 36.2 ±o.3°C T•• in NR and 35.7 ± 0.3°C in SI-IR. 
• body temperatures between the V ! The difference in the ini tial e groups is not statistically ~Jl __....-- _,_ significant. The differences in 
~-·~ the PGFß-induced changes be-
tween SHR and NR are shown by 
~I 0.5 5 
PGF2cx (~/rat i.c.v.) 
asterisks; • p<O .OS and • • 
p<O.OOS. Vertical bars indicate 
s.e.m. Each group comprised 6 
50 rats. 
DISCUSSION 
Arachidonic acid (AA) raised the blood pressure, when administered i.c.v. 
to urethane-anaesthetised spontaneously hypertensive Okamoto-Aoki rats (SHR) or 
normotensive Wistar rats (NR). These results are in agreernent with our previous 
findings that i.c.v. a~nistered AA induced increases in blood pressure of NR 
(4). The M-induced hypertensive effect was larger in magnitude in SHR than in 
NR. Though conscious SHR had significantly higher systolic blood pressure lev-
el than NR, there was no significant difference in the baseline mean blood pres-
sure between SHR and NR lDlder urethane anaesthesia. M. i.c.v. increased signif-
icantly also the heart rate and body temperature in NR, but in SHR i t induced 
only negligible rise of body temperature and had no clear effect on heart rate. 
The AA-induced changes in blood pressure, heart rate and body temperature were 
not due to any leakage of this agent into the peripheral circulation but to an 
action upon the central nervaus system, since the same doses of AA did not af-
fect significantly the body temperature and even slightly decreased the blood 
pressure and heart rate following intravenous administrations. In the present 
study the normotensive control rats were of the Wistar strain and not of the 
Wistar-Kyoto strain (WKY) which is the antecedent colony of SHR (16). However, 
no significant difference in the hypotensive response to intra-arterially in-
jected AA between WKY and NRwas reported (12). Furthermore, the central pres-
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sor response to PGE 2 in NR did not differ from that in WKY but was significant-
ly greater in SHR than in WKY or NR (13). The present difference in the central 
hypertensive action of AA between SHR and NR seems thus to be associated with 
the high blood pressure in SHR rather than to sore genetic differences between 
WKY and NR. Sodiun ooclofenamate, an inhibitor of prostaglandin synthesis(17), 
antagonised the central cardiovascular and thennal effects of AA in NR indicat-
ing that the centra1 actions of M were JOOdiated by i ts mtaboli tes and not by 
M itself. In a previous study the hypertensive effect of M i.c.v. was antag-
onised by central pretreatment with indamethacin or paracetamol {18),two inhib-
i tors of the prostaglandin synthesis in the brain (19) . PGD 2 , PGF 2!1. and TxA2 
are the major IIEtabolites of M in the homogenates of the rat brain (1,3). High 
activi ty of PGD syntheta.se has been also detected in various regions of the rat 
brain (20). Since PGD 2 is a potent activator of the cyclic m.cleotide adenyla-
te cyclase system of cul tured neuroblastoma cells, the role of a new-olOOdulator 
for PGD 2 in the brain has been suggested (20). However, PGD 2 at the i.c.v. do-
ses of 1 or 10 ~rat had no significant cardiovascular or thermal effect in 
conscious rats (9). In a previous study we obtained dose-related increases in 
heart rate and body tempera ture of urethane-anaes thetised NR following i • c. v. 
administration of 0.001-100 ug/rat doses of PGD 2 , whi1e the blood pressure re-
sponse to centrally applied PGD2 was not consistent(6,own tmpublished results). 
The central effects of PGD 2 were also considerable smaller in magni tude than 
those induced by the same doses of PGE 2 (6) or PGF Zl (5). Thus PGD 2 seems to 
interfere preferentia1ly wi th the central regulation of heart rate and body tem· 
perature but only minimally wi th the central b1ood pressure regulation of the 
rat. Imidazole, an inhibi tor of TxA 2 synthesis (21), antagonised the cen:tral 
hypertensive effect of M in NR (18), but the central effects of TxA 2 i tself 
have not been reported. Unlike PGD 2 , PGF~ and PGE 2 i.c.v. induce strong hy-
pertensive, tachycardic and hyperthennic effects in NR (5,6,22,23). However, 
PGF 21- had no significant central effects on b1ood pressure, heart rate or body 
teJit>erature in SHR. Recent studies have shown that the synthesis of PGE 2 is 
increased and the ratio PGI 2/PGE 2 is decreased in the brain-stem of stroke-re-
sistantant SHR (10). Intracerebroventricularly, PGE 2 is thus hypertensive (6, 
7), while PGI 2 induce hypotension (7 ,8). Since M is the precursor of prosta-
glandins in the rat brain (2), the potentiation of the central hypertensive ef-
fect of M in SHR might be due to an increased formation of hypertensive prosta-
glandins other than PGF 2a in the brain. The recent finding by Takahashi and 
Bufiag (13) that the central presser response to PGE 2 was greater in SHR than in 
NR further suggests that an increased receptor sensibi1i ty to PGE 2 or to sore 
other hypertensive IIEtabolite of M other than PGF2l in the brain might contri-
bute to the strong central hypertensive effect of M in SHR. 
The tachycardic response to i.c.v. adrninistered AA was not dose-related in 
SHR. The central hyperthermic response to M ,was also negligible in these ra ts 
However, in NR i.c.v. administered AA caused significant increases in the heart 
rate and body teßt>erature. Since the hypertensive. effect of M i.c.v. was 
significantly greater in SHR than in NR, the presser response to M might be 
IIEdiated by different centra1 mechanisms than its tachycardic and hyperthennic 
effects. In agreeiOOnt with the present findings the hypertensive effect of 
centrally administered PGE2 was potentiated in SHR but not the tachycardic ef-
fect of this agent (13). The greater blood pressure effect of centrally admin-
istered M in SHR might therefore be due to an increased fonnation of PGE 2 in 
the brain, while the actions of M heart rate and body teJil>erature might re-
quire the synthesis of other prostaglandins. 
Recent studies have shown that intra-arteria1 injection of AA at the doses 
of 0.1-1 ).01I)les/kg induce significantly sma1ler hypotensive effect in SHR than 
in WKY or NR suggesting that the release of vasodepressor prostaglandins from 
blood vessels of Slm might be reduced (12) . Similarly, the blood pressure low-
ering effect of intravenously administered M, PGE2 or PGI2 was significantly 
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attenuated in unclipped renal hypertensive rats (24). However, arterial tissue 
from SHR releases more PGE2(ZS) and PGI 2 (26) than the vascular tissue obtained 
from NR. Other studies have indicated that a defect in the renal prostaglandin 
catabolism might be an inq)ortant factor in the development of high blood pres-
sure in the New Zealand strain of genetically hypertensive rats (27}. It has 
also been reported that the synthesis of PGF2a, a streng vasoconstrictor in 
rats (28), is increased in the renal papilla of SHR (29). The present results 
obtained with AA i.c.v. lend further support to the suggestions that the hypo-
tensive prostaglandin/hypertensive prostaglandin ratio might be decreased even 
in the central nervous system of SHR. However, the failure of PGF20- i.c.v. to 
induce cardiovascular and thermal effects in SHR contradicts the possibility 
tha t an increased fonna tion of PGF20- in the brain tissue of SHR could be asso-
ciated with the high blood pressur~. 
In agreement with a previous study (5) PGF2a i.c.v. induced strong dose-
related hypertensive, tachycardic and hyperthermic effects in NR. When admin-
istered i.c.v. to SHR PGF2a had no significant effect on blood pressure, heart 
rate or body temperature. SHR had about 25 mm Hg higher initial blood pressure 
level even during urethane anaesthesia than NR. However, there was no signif-
icant difference in the baseline values for heart rate or body temperature be-
tween SHR and NR. Recent studies have shown that the synthesis of PGFß and 
the ratio PGF2a /PGE2 are decreased in the brain horogenates of SHR (11). When 
also the formation of PGE2 is increased in the brain-stem of SHR (10), the pos-
sibility .. might:.-e.Xist that PGE 2or soiOO other metabolites of M other than PGF2a 
in the brain are involved.in the central cardiovascular and thermal regulation 
of SHR. However, PGF2a seems to be associated with the central cardiovascular 
and thennal regulation in NR. The central effects of PGFZl in NR are likely to 
be due to an activation of the sympathetic nervaus system (30,31). l\breover, 
atropine antagonised the central cardiovascular effects of PGF2a in NR (22). 
Cbolinamimetic drugs and PGF2a both increased b1ood pressure and sympathetic 
activit:y in NR, when injected i.c.v. or into the posterior hypothalamic nuc1ei 
(30,32,33). Further.more, cho1inergic mechanisms in the posterior hypothalamus 
mdiated also the hyperthennic effect of prostag1andins (34). Since recent 
studies have shown that the activi ty of the cholinergic system in the posterior 
hypothalamus is decreased in SHR (35), the lack of the centra1 cardiovascular 
and thermal effects of PGF~ in SHR might be due to a dysftmction of the central 
cholinergic JOOchanisms. However, various other central JOOchanisms have been 
also ilqllicated in the etiology of spontaneaus hypertension (33). Therefore the 
present finding may warrant further investigation. 
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